Below are the most recent publications written about "Immunotherapy, Adoptive" by people in Profiles.
-
Seyedin R, Snider JT, Rajagopalan K, Wade SW, Gergis U. Chimeric antigen receptor T-cell treatment patterns in relapsed or refractory large B-cell lymphoma. Future Oncol. 2023 Jul; 19(22):1535-1547.
-
Cowan AJ, Pont MJ, Sather BD, Turtle CJ, Till BG, Libby EN, Coffey DG, Tuazon SA, Wood B, Gooley T, Wu VQ, Voutsinas J, Song X, Shadman M, Gauthier J, Chapuis AG, Milano F, Maloney DG, Riddell SR, Green DJ. ?-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial. Lancet Oncol. 2023 Jul; 24(7):811-822.
-
Yi D, Gergis M, Hsu J, Yang Y, Bi X, Aljurf M, Gergis U. Next-Generation Chimeric Antigen Receptor T-cells. Hematol Oncol Stem Cell Ther. 2022 Dec 15; 15(3):117-121.
-
Yi D, Gergis M, Elgohary G, Hsu J, Yang Y, Bi X, Gergis U. Chimeric Antigen Receptor T-cell Therapies in Lymphoma Patients with Central Nervous System Involvement. Hematol Oncol Stem Cell Ther. 2022 Dec 15; 15(3):66-72.
-
Bi X, Hsu J, Gergis M, Yang Y, Yi D, Gergis U. Chimeric Antigen Receptor T-cell Therapy for Acute Myeloid Leukemia. Hematol Oncol Stem Cell Ther. 2022 Dec 15; 15(3):131-136.
-
Hsu J, Yang Y, Gergis M, Bi X, Yi D, Gergis U. Chimeric Antigen Receptor T Cell Therapy For Solid Tumors. Hematol Oncol Stem Cell Ther. 2022 Dec 15; 15(3):94-99.
-
Singh H, Srour SA, Milton DR, McCarty J, Dai C, Gaballa MR, Ammari M, Olivares S, Huls H, De Groot E, Marin D, Petropoulos D, Olson AL, Anderlini P, Im JS, Khouri I, Hosing CM, Rezvani K, Champlin RE, Shpall EJ, Cooper LJN, Kebriaei P. Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies. Front Immunol. 2022; 13:1032397.
-
Wood AC, Perez AP, Arciola B, Patel K, Johnson G, DiMaggio E, Bachmeier CA, Reid K, Carallo S, Vargas MH, Faramand R, Chavez JC, Shah B, Gaballa S, Khimani F, Elmariah H, Nishihori T, Lazaryan A, Freeman C, Davila ML, Locke FL, Mhaskar R, Bassil C, Jain MD. Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis. Transplant Cell Ther. 2022 12; 28(12):829.e1-829.e8.
-
Gaballa MR, Maus MV. High antigen density of BCMA: friend or foe to CAR T cells? J Immunother Cancer. 2022 09; 10(9).
-
Perez A, Johnson G, Patel K, Arciola B, Wood A, Bachmeier CA, Chavez JC, Shah BD, Khimani F, Nishihori T, Lazaryan A, Davila ML, Mhaskar R, Locke FL, Gaballa S, Jain MD. Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL. Blood Adv. 2022 Jul 12; 6(13):3970-3973.